NetraMark has released a new clinical trial de-risking technology called NetraGPT, which integrates ChatGPT.
NetraGPT is based on hypotheses created from the firm’s proprietary good clinical practice (GCP) validated AI/ML system known as NetraAI.
Go deeper with GlobalData
The NetraAI system has the capability to learn special combinations of variables that define patient subpopulations in the context of drug or placebo responses and adverse effects, which are important aspects of clinical trials.
NetraGPT consumes data on specific clinical trial patient subpopulations identified by NetraAI.
This process includes feeding various variables, biological or otherwise, which are statistically important for the discovered subpopulations, based on the dependent variable, such as drug response, placebo response, placebo non-response, adverse events, and others.
See Also:
Based on these feeds, NetraGPT provides comprehensive, human-readable reports driven by large language models (LLMs).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNetraGPT also offers output reports that start assembling in seconds and complete within minutes.
It further provides enhanced explainability of the influential variables underlying discovered subpopulations, as well as new insights outlining interconnections among variables, responses, and the state of the disease.
In addition, references taken from relevant and contemporary literature are offered by NetraGPT.
The technology uses a transparent process involving the variables supporting the specific patient subpopulations that can be clearly recognised and confirmed via statistical assessment.
The transparency helps sponsors, especially when working with LLMs, as it allows trialists and human experts to audit portions of the hypothesis-generation artificial intelligence (AI) process and the LLM-generated report.
NetraMark CTO and CSO Dr Joseph Geraci said: “LLMs, like ChatGPT, have recently achieved a level of sophistication that is enabling practical innovation for a variety of use cases.
“NetraAI is built to explain what it finds and this property makes our technology an optimal partner for ChatGPT.
“Through new algorithm development at NetraMark, this fusion between NetraAI and ChatGPT provides a cutting edge insight engine for clinical trial patient populations that can be delivered quickly and with clarity.”
